# Patent

## Title
4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments

## Abstract

The present invention encompasses compounds of general formula (1)




wherein X and R1 to R3 are as defined in the disclosure, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.

## Background
This application is a U.S. National Stage application of PCT/EP2007/056853 filed Jul. 5, 2007, which claims the benefit of EP06116748.2, filed on Jul. 6, 2006.
NEW COMPOUNDS
The present invention relates to new 4-heterocycloalkylpyrimidines of general formula (1)




wherein the groups X and R1 to R3 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these compounds and their use as medicaments.



DETAILED DESCRIPTION OF THE INVENTION
It has now surprisingly been found that compounds of general formula (1) wherein the groups X, R1, R2 and R3 have the meanings given hereinafter act as inhibitors of specific cell cycle kinases. Thus, the compounds according to the invention may be used for example for the treatment of diseases connected with the activity of specific cell cycle kinases and characterised by excessive or abnormal cell proliferation.
The present invention relates to compounds of general formula (1)




wherein

X denotes CH or N, and

R1 denotes 8-12 membered heterocycloalkyl, optionally substituted by one or more identical or different R4, and

R2 denotes a group selected from among C6-15aryl, 3-8 membered heterocycloalkyl and 5-14 membered heteroaryl, substituted by one or more identical or different R4, and

R3 denotes a group selected from among halogen, —CN, —NRfRf, —ORf, —C(O)Rf, —SRf, —S(O)Rf, —S(O)2Rf, C1-4alkyl, C1-4haloalkyl, C3-5cycloalkyl and 3-5 membered heterocycloalkyl, and

R4 denotes a group selected from among Ra, Rb and Ra substituted by one or more identical or different Rc and/or Rb;

each Ra is selected independently of one another from among C1-6alkyl, C3-10cycloalkyl, C4-16cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl;

each Rb is a suitable group and each is independently selected from among ═O, —ORc, C1-3haloalkyloxy, —OCF3, ═S, —SRc, ═NRc, ═NORc, —NRcRc, halogen, —CF3, —CN, —NC, —OCN, —SCN, —NO2, —S(O)Rc, —S(O)2Rc, —S(O)2ORc, —S(O)NRcRc, —S(O)2NRcRc, —OS(O)Rc, —OS(O)2Rc, —OS(O)2ORc, —OS(O)2NRcRc, —C(O)Rc, —C(O)ORc, —C(O)NRcRc, —CN(Rf)NRcRc, —CN(OH)Rc, —CN(OH)NRcRc, —OC(O)Rc, —OC(O)ORc, —OC(O)NRcRc, —OCN(Rf)NRcRc, —N(Rf)C(O)Rc, —N(Rf)C(S)Rc, —N(Rf)S(O)2Rc, —N(Rf)C(O)ORc, —N(Rf)C(O)NRcRc, —[N(Rf)C(O)]2Rc, —N[C(O)]2Rc, —N[C(O)]2Rc, —[N(Rf)C(O)]2ORc and —N(Rf)CN(Rf)NRcRc;

each Rc independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rd and/or Re selected from among C1-6alkyl, C3-10cycloalkyl, C4-11cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl;

each Rd independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Re and/or Rf selected from among C1-6alkyl, C3-8cycloalkyl, C4-11cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl;

each Re is a suitable group and each is independently selected from among ═O, —ORf, C1-3haloalkyloxy, —OCF3, ═S, —SRf, ═NRf, ═NORf, —NRfRf, halogen, —CF3, —CN, —NC, —OCN, —SCN, —NO2, —S(O)Rf, —S(O)2Rf, —S(O)2ORf, —S(O)NRfRf, —S(O)2NRfRf, —OS(O)Rf, —OS(O)2Rf, —OS(O)2ORf, —OS(O)2NRfRf, —C(O)Rf, —C(O)ORf, —C(O)NRfRf, —CN(Rg)NRfRf, —CN(OH)Rf, —C(NOH)NRfRf, —OC(O)Rf, —OC(O)ORf, —OC(O)NRfRf, —OCN(Rg)NRfRf, —N(Rg)C(O)Rf, —N(Rg)C(S)Rf, —N(Rg)S(O)2Rf, —N(Rd)C(O)ORf, —N(Rg)C(O)NRfRf, and —N(Rg)CN(Rf)NRfRf;

each Rf independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rg selected from among C1-6alkyl, C3-8cycloalkyl, C4-11cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl;
each Rg independently of one another denotes hydrogen, C1-6alkyl, C3-8cycloalkyl, C4-11cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl, optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof, with the proviso that carries at least one substituent different from halogen and the following compounds are not included:

    4-[5-chloro-4-(4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl)-pyrimidin-2-ylamino]-N,N-dimethyl-phenylsulphonamide, (2-99)
    4-[5-chloro-4-(1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-pyrimidin-2-ylamino]-N,N-dimethyl-phenylsulphonamide (2-136)
    N,N-dimethyl-4-[5-methyl-4-(1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-pyrimidin-2-ylamino]-phenylsulphonamide, (2-143)
    N,N-dimethyl-4-[5-methyl-4-(4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl)-pyrimidin-2-ylamino]-phenylsulphonamide, (2-144)
    2-(4-(1-piperidinyl-methyl-)phenylamino)-4-(1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-trifluoromethyl-pyrimidine; (1-006)
    2-[4-(1,2,4,5-tetrahydro-benzo[d]azepin-3-ylmethyl)-phenylamino]-4-(1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-trifluoromethyl-pyrimidine; (1-646)
    N,N-dimethyl-4-[4-(4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl)-5-trifluoromethyl-pyrimidin-2-ylamino]-phenylsulphonamide, (2-73)
    N,N-dimethyl-4-[4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-trifluoromethyl-pyrimidin-2-ylamino]-phenylsulphonamide, (1-694)
    [4-(morpholin-4-sulphonyl)-phenyl]-[4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-trifluoromethyl-pyrimidin-2-yl]-amine, (1-695)
    [5-methoxy-4-(1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-pyrimidin-2-yl]-(4-piperidin-1-ylmethyl-phenyl)-amine, (2-139)
    N5,N5-dimethyl-N2-(4-piperidin-1-ylmethyl-phenyl)-4-(1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-pyrimidine-2,5-diamine, (2-145)
    [5-isopropyl-4-(1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-pyrimidin-2-yl]-(4-piperidin-1-ylmethyl-phenyl)-amine, (2-146) 2-4-(carboxy-phenylamino)-4-(1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-trifluoromethyl-pyrimidine (1-017)
    2-4-(2-carboxy-1-ethyl-)phenylamino)-4-(1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-trifluoromethyl-pyrimidine (1-023).


In one aspect the invention relates to compounds of general formula (1), wherein X denotes N.
In another aspect the invention relates to compounds of general formula (1), wherein R3 denotes a group selected from among halogen, —NRfRf, —ORf, —C(O)Rf, C1-4alkyl, C1-4haloalkyl and C3-5cycloalkyl.
In another aspect the invention relates to compounds of general formula (1), wherein R2 denotes a group selected from among phenyl and 5-12 membered heteroaryl.
In another aspect the invention relates to compounds of general formula (1A),




wherein

Q denotes 5, 6 or 7 membered heterocycloalkyl and

R2, R3 and R4 are as hereinbefore defined.

(A) Aspects relating to R1.
(A1) In one aspect the invention relates to compounds of general formula (1), wherein R1 denotes 1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl.
(A2) In another aspect the invention relates to compounds of general formula (1), wherein R1 denotes 4,5,7,8-tetrahydro-1H-imidazo[4,5-d]azepin-6-yl.
(B) Aspects relating to R2.
(B1) In one aspect the invention relates to compounds of general formula (1), wherein R2 denotes 9 membered heteroaryl, substituted by one or more identical or different R4.
(B2) In another aspect the invention relates to compounds of general formula (1), wherein R2 denotes 9 membered heterocycloalkyl substituted by one or more identical or different R4.
(B3) In another aspect the invention relates to compounds of general formula (1), wherein R2 denotes phenyl substituted by a 5-6 membered heterocycloalkyl, which may optionally be substituted by one or more identical or different Rc and/or Rb.
(B4) In another aspect the invention relates to compounds of general formula (1), wherein R2 denotes phenyl substituted by —NRcRc.
(B5) In another aspect the invention relates to compounds of general formula (1), wherein R2 denotes phenyl substituted by —C(O)Rc.
(B6) In another aspect the invention relates to compounds of general formula (1), wherein R2 denotes phenyl substituted by —C(O)NRcRc.
(C) Aspects relating to R3.
(C1) In one aspect the invention relates to compounds of general formula (1), wherein R3 denotes dimethylamino.
(C2) In another aspect the invention relates to compounds of general formula (1), wherein R3 denotes methoxy.
All the above mentioned aspects (A1) and (A2) for R1, (B1) to (B6) for R2 and (C1) and (C2) for R3 may be combined with one another as desired.
The following Table shows preferred combinations of different aspects of the compounds of formula I according to the invention:
















embodiment
R1
R2
R3









I-1
A1
B1
C1



I-2
A1
B2
C1



I-3
A1
B3
C1



I-4
A1
B4
C1



I-5
A1
B5
C1



I-6
A1
B6
C1



I-7
A2
B1
C1



I-8
A2
B2
C1



I-9
A2
B3
C1



I-10
A2
B4
C1



I-11
A2
B5
C1



I-12
A2
B6
C1



I-13
A1
B1
C2



I-14
A1
B2
C2



I-15
A1
B3
C2



I-16
A1
B4
C2



I-17
A1
B5
C2



I-18
A1
B6
C2



I-19
A2
B1
C2



I-20
A2
B2
C2



I-21
A2
B3
C2



I-22
A2
B4
C2



I-23
A2
B5
C2



I-24
A2
B6
C2










In another aspect the invention relates to compounds of general formula (1) or (1A), or the pharmaceutically effective salts thereof, for use as pharmaceutical compositions.
In another aspect the invention relates to compounds of general formula (1) or (1A), or the pharmaceutically effective salts thereof, for preparing a pharmaceutical composition with an antiproliferative activity.
In another aspect the invention relates to pharmaceutical preparations containing as active substance one or more compounds of general formula (1) or (1A), or the pharmaceutically effective salts thereof optionally in combination with conventional excipients and/or carriers.
In another aspect the invention relates to the use of compounds of general formula (1) or (1A) for preparing a pharmaceutical composition for the treatment and/or prevention of cancer, infections, inflammations and autoimmune diseases.
In another aspect the invention relates to a pharmaceutical preparation comprising a compound of general formula (1) or (1A) and at least one other antiproliferative active substance, different from formula (1) or (1A), optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmaceutically effective salts thereof.
DEFINITIONS
As used herein, the following definitions apply, unless stated otherwise.
By alkyl substituents are meant in each case saturated, unsaturated, straight-chain or branched aliphatic hydrocarbon groups (alkyl group) and this includes both saturated alkyl groups and unsaturated alkenyl and alkynyl groups. Alkenyl substituents are in each case straight-chain or branched, unsaturated alkyl groups, which have at least one double bond. By alkynyl substituents are meant in each case straight-chain or branched, unsaturated alkyl groups, which have at least one triple bond.
Heteroalkyl represents unbranched or branched aliphatic hydrocarbon chains which contain 1 to 3 heteroatoms, while each of the available carbon and heteroatoms in the heteroalkyl chain may optionally each be substituted independently and the heteroatoms independently of one another are selected from among O, N, P, PO, PO2, S, SO and SO2 (e.g. dimethylaminomethyl, dimethylaminoethyl, dimethylaminopropyl, diethylaminomethyl, diethylaminoethyl, diethylaminopropyl, 2-diisopropylaminoethyl, bis-2-methoxyethylamino, [2-(dimethylamino-ethyl)-ethyl-amino]-methyl, 3-[2-(dimethylamino-ethyl)-ethyl-amino]-propyl, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, methoxy, ethoxy, propoxy, methoxymethyl, 2-methoxyethyl).
Haloalkyl refers to alkyl groups wherein one or more hydrogen atoms are replaced by halogen atoms. Haloalkyl includes both saturated alkyl groups and unsaturated alkenyl and alkynyl groups, such as for example —CF3, —CHF2, —CH2F, —CF2CF3, —CHFCF3, —CH2CF3, —CF2CH3, —CHFCH3, —CF2CF2CF3, —CF2CH2CH3, —CF═CF2, —CCl═CH2, —CBr═CH2, —CI═CH2, —C≡C—CF3, —CHFCH2CH3 and —CHFCH2CF3.
Halogen refers to fluorine, chlorine, bromine and/or iodine atoms.
By cycloalkyl is meant a mono- or polycyclic ring, wherein the ring system may be a saturated ring but also an unsaturated, non-aromatic ring or a spiro compound, which may optionally also contain double bonds, such as for example cyclopropyl, cyclopropenyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptanyl, cycloheptenyl, norbornyl, norbornenyl, indanyl, adamantyl, spiroheptanyl and spiro[4.2]heptanyl.
Cycloalkylalkyl includes a non-cyclic alkyl as hereinbefore defined wherein a hydrogen atom bound to a carbon atom is replaced by a cycloalkyl group.
Aryl relates to monocyclic or bicyclic rings with 6-12 carbon atoms such as for example phenyl and naphthyl.
Arylalkyl includes a non-cyclic alkyl group wherein a hydrogen atom bound to a carbon atom is replaced by an aryl group.
By heteroaryl are meant mono- or polycyclic rings which contain, instead of one or more carbon atoms, one or more heteroatoms, which may be identical or different, such as e.g. nitrogen, sulphur or oxygen atoms. Examples include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl and triazinyl. Examples of bicyclic heteroaryl groups are indolyl, isoindolyl, benzofuranyl, benzothienyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, indazolyl, isoquinolinyl, quinolinyl, quinoxalinyl, cinnolinyl, phthalazinyl, quinazolinyl and benzotriazinyl, indolizinyl, oxazolopyridinyl, imidazopyridinyl, naphthyridinyl, indolinyl, isochromanyl, chromanyl, tetrahydroisoquinolinyl, isoindolinyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, isobenzothienyl, benzoxazolyl, pyridopyridinyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, purinyl, benzodioxolyl, triazinyl, phenoxazinyl, phenothiazinyl, pteridinyl, benzothiazolyl, imidazopyridinyl, imidazothiazolyl, dihydrobenzisoxazinyl, benzisoxazinyl, benzoxazinyl, dihydrobenzisothiazinyl, benzopyranyl, benzothiopyranyl, coumarinyl, isocoumarinyl, chromonyl, chromanonyl, pyridinyl-N-oxide tetrahydroquinolinyl, dihydroquinolinyl, dihydroquinolinonyl, dihydroisoquinolinonyl, dihydrocoumarinyl, dihydroisocumarinyl, isoindolinonyl, benzodioxanyl, benzoxazolinonyl, pyrrolyl-N-oxide, pyrimidinyl-N-oxide, pyridazinyl-N-oxide, pyrazinyl-N-oxide, quinolinyl-N-oxide, indolyl-N-oxide, indolinyl-N-oxide, isoquinolyl-N-oxide, quinazolinyl-N-oxide, quinoxalinyl-N-oxide, phthalazinyl-N-oxide, imidazolyl-N-oxide, isoxazolyl-N-oxide, oxazolyl-N-oxide, thiazolyl-N-oxide, indolizinyl-N-oxide, indazolyl-N-oxide, benzothiazolyl-N-oxide, benzimidazolyl-N-oxide, pyrrolyl-N-oxide, oxadiazolyl-N-oxide, thiadiazolyl-N-oxide, triazolyl-N-oxide, tetrazolyl-N-oxide, benzothiopyranyl-S-oxide and benzothiopyranyl-S,S-dioxide.
Heteroarylalkyl encompasses a non-cyclic alkyl wherein a hydrogen atom bound to a carbon atom is replaced by a heteroaryl group.
Heterocycloalkyl relates to saturated or unsaturated, non-aromatic mono-, polycyclic or bridged polycyclic rings or spiro compounds comprising 3-12 carbon atoms, which carry heteroatoms, such as nitrogen, oxygen or sulphur, instead of one or more carbon atoms. Examples of such heterocyclyl groups are tetrahydrofuranyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidinyl, piperazinyl, indolinyl, isoindolinyl, morpholinyl, thiomorpholinyl, homomorpholinyl, homopiperidinyl, homopiperazinyl, homothiomorpholinyl, thiomorpholinyl-S-oxide, thiomorpholinyl-S,S-dioxide, tetrahydropyranyl, tetrahydrothienyl, homothiomorpholinyl-S,S-dioxide, oxazolidinonyl, dihydropyrazolyl, dihydropyrrolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydrofuryl, dihydropyranyl, tetrahydrothienyl-S-oxide, tetrahydrothienyl-S,S-dioxide, homothiomorpholinyl-S-oxide, 2-oxa-5-azabicyclo[2.2.1]heptane, 8-oxa-3-aza-bicyclo[3.2.1]octane, 3,8-diaza-bicyclo[3.2.1]octane, 2,5-diaza-bicyclo[2,2,1]heptane, 3,8-diaza-bicyclo[3.2.1]octane, 3,9-diaza-bicyclo[4.2.1]nonane and 2,6-diaza-bicyclo[3.2.2]nonane.
Heterocycloalkylalkyl relates to a non-cyclic alkyl group wherein a hydrogen atom bound to a carbon atom is replaced by a heterocycloalkyl group.
By the word “substituted” is meant that a hydrogen atom which is bound directly to the atom in question is replaced by a different atom or a different atomic group. Bivalent substituents such as ═O, ═S, ═NR, ═NOR, ═NNRR, ═NN(R)C(O)NRR, ═N2 and others demand substitution by two hydrogen atoms which are bound directly to the atom in question. Accordingly, bivalent substituents of this kind may not be substituents in aromatic systems.










List of abbreviations


















DMA
N,N-dimethylacetamide
min
minute(s)


DMF
N,N-dimethylformamide
MS
mass spectrometry


DMSO
dimethylsulphoxide
RP
Reversed phase


Et
ethyl
RT
room temperature


h
hour(s)
sec
second(s)


HPLC
high performance liquid
THF
tetrahydrofuran



chromatography


Me
methyl
UV
ultraviolet









PREPARATION OF THE COMPOUNDS ACCORDING TO THE INVENTION
The compounds according to the invention may be prepared according to the methods of synthesis described hereinafter, wherein the substituents of general formulae (I to XIV) have the meanings given hereinbefore.
Method
Step 1
The preparation of the intermediate compound III is carried out by substitution of a leaving group (LG), for example halogen, SCN or methoxy, preferably chlorine, in a heteroaromatic system I by a nucleophile II.




1 equivalent of compound I and 1-1.5 equivalents of compound II are stirred in a solvent, for example 1,4-dioxane, THF, DMF, DMA or 2-butanol. At a temperature of 15-25° C. 2-2.5 equivalents of a base, for example potassium carbonate, sodium carbonate, caesium carbonate, ethyldiisopropylamine or triethylamine, are added. The reaction mixture is stirred for a further 12-72 h at a temperature of 15-50° C. Then the solvent is distilled off and the residue is purified by chromatography.
Step 2
The preparation of the end compound V is carried out by substitution of a leaving group LG, for example halogen, SCN or methoxy, preferably chlorine, in a heteroaromatic system III by a nucleophile IV.




1 equivalent of the compound III and 1-3 equivalents of the compound IV are stirred in a solvent, for example 1,4-dioxane, DMF, DMA, N-methyl-2-pyrrolidinone or water. At a temperature of 15-40° C. 1-2 equivalents of an inorganic acid, for example sulphuric acid or hydrochloric acid, are added. The reaction mixture is stirred for a further 12-72 h at a temperature of 20-100° C. Then the solvent is distilled off and the residue is purified by chromatography.
Step 3A
For groups R2 which contain, in addition to the N atom mentioned above, another N atom, a carbonyl group, a halogen atom or another functional group, there is the possibility of further derivatisation to obtain the product VIII. For example it is possible to react molecules which have a further N atom with a reactant having a carbonyl group (VII).




1 equivalent of the compound VI and 1-2 equivalents of the compound VII are stirred in a solvent, for example methanol or DMA. At a temperature of 15-25° C., 2-5 equivalents of a reducing agent, for example sodium triacetoxyborohydride or sodium cyanoborohydride, are added. The reaction mixture is stirred for a further 0.5-18 h at a temperature of 15-25° C., then combined with water, which has been adjusted to a pH of 8 to 9 with an inorganic base, for example sodium hydrogen carbonate, potassium carbonate or sodium hydroxide. This mixture is extracted two to three times with an organic solvent, for example diethyl ether, ethyl acetate or dichloromethane. The combined organic extracts are dried and the solvent is distilled off. The residue is purified by chromatography or repeated crystallisation.
Step 3B
In addition, molecules with a carbonyl group may be reacted with an amine.




1 equivalent of the compound IX and 1-2 equivalents of the compound X are stirred in a solvent, for example methanol or DMA. At a temperature of 15-25° C., 2-5 equivalents of a reducing agent, for example sodium triacetoxyborohydride or sodium cyanoborohydride, are added. The reaction mixture is stirred for a further 0.5-18 h at a temperature of 15-25° C., then combined with water, which has been adjusted to a pH of 8 to 9 with an inorganic base, for example sodium hydrogen carbonate, potassium carbonate or sodium hydroxide. This mixture is extracted two to three times with an organic solvent, for example diethyl ether, ethyl acetate or dichloromethane. The combined organic extracts are dried and the solvent is distilled off. The residue is purified by chromatography or repeated crystallisation.
Step 3C
Molecules with an additional N atom may be reacted with an alkyl halide (alkyl-Hal).




1 equivalent of the compound VI and 1-10 equivalents of the compound XII are stirred in a solvent, for example 1,4-dioxane, THF, DMF or acetonitrile. At a temperature of 15-25° C., 2-2.5 equivalents of a base, for example potassium carbonate, sodium carbonate, caesium carbonate, ethyldiisopropylamine or triethylamine, are added. The reaction mixture is stirred for a further 12-72 h at a temperature of 15-25° C., then combined with water, which has been adjusted to a pH of 8-9 with an inorganic base, for example sodium hydrogen carbonate or potassium carbonate. This mixture is extracted two to three times with an organic solvent, for example diethyl ether, ethyl acetate or dichloromethane. The combined organic extracts are dried and the solvent is distilled off. The residue is purified by chromatography or repeated crystallisation.
Step 3D
Molecules that have a carboxyl group may be reacted with an amine. If the carboxyl group is present in a protected form it is converted into the deprotected compound beforehand by hydrolysis or similar methods known to the skilled man.




1 equivalent of the compound XIV, 1-1.5 equivalents of the compound X and 1-3 equivalents of a base, for example triethylamine or ethyldiisopropylamine, are stirred in a solvent, for example 1,4-dioxane, DMF, DMA or N-methyl-2-pyrrolidinone. At a temperature of 15-25° C., 1-1.5 equivalents of a coupling reagent, for example N,N-dicyclohexylcarbodiimide, N,N-diisopropylcarbodiimide, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium-tetrafluoroborate, 1-(3-N,N-dimethylaminopropyl)-3-ethylcarbodiimide or O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate, are added. The reaction mixture is stirred for a further 4-24 h at a temperature of 15-25° C. Then the solvent is distilled off and the residue is purified by chromatography.
Chromatography
For the preparative medium pressure chromatography (MPLC) silica gel obtained from Millipore (Granula Silica Si-60A 35-70 μm) or C-18 RP silica gel obtained from Macherey Nagel (Polygoprep 100-50 C18) is used.
For the high pressure chromatography, columns made by Waters (XTerra Prep. MS C18, 5 μM, 30*100 mm, Symmetrie C18, 5 μm, 19*100 mm or XBridge C18, 5 μm, 19*100) are used.
Mass Spectroscopy/UV-Spectrometer:
These data are produced using an HPLC-MS apparatus (high performance liquid chromatography with mass detector) made by Agilent.
The apparatus is constructed so that the chromatography (column: Zorbax SB-C8, 3.5 μm, 2.1*50, Agilent) is followed by a diode array detector (G1315B made by Agilent) and a mass detector (1100 LS-MSD SL; G1946D; Agilent) connected in series.
This apparatus is operated with a flow of 0.6 mL/min. For a separation process a gradient is run through within 3.5 min (gradient at the start: 95% water and 5% acetonitrile, gradient at the finish: 5% water and 95% acetonitrile; as buffer, either 0.1% formic acid is added to both solvents, or 5 mM ammonium hydrogen carbonate and 19 mM ammonia are added to the water).
Starting Materials
Where the preparation of the starting compounds has not been described, these are commercially obtainable, known from the literature or are easily obtained by the skilled man using general methods.

    (2,4-dichloro-pyrimidin-5-yl)-dimethyl-amine and derivatives (O'Brien, Darrell E. et al., J. Med. Chem. (1966), 9, 121)
    4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (T. Vitali et al., Farmacao, Ed. Sci. 20, 636 (1969))
    1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (R. Jain, L. A. Cohen, Tetrahedron, 52 (15) 5363 (1996) or T. Vitali et al., Farmacao, Ed. Sci. 20, 636 (1969))
    3-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (G. Durant et. al, J. Med. Chem. (1976), 19, 923 or T. Vitali et al., Farmacao, Ed. Sci. 20, 636 (1969))
    4,5,6,7-tetrahydro-1H-imidazo[4,5-d]-azepine (WO 03/032997)
    2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-d]-azepine (WO 03/032997)
    2-thiomethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-d]-azepine (analogously to 2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-d]-azepine with S-methylthiourea)
    N-(3-aminophenyl)pyrrolidine-1-carboxamide (WO 2004/048343)
    4-morpholin-4-yl-cyclohexylamine and 4-morpholin-4-yl-cyclobutylamine (WO 2006/021544)
    2-thiomethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-d]-azepine (analogously to 2-methyl-4,5,6,7-tetrahydro-1H-imidazol[4,5-d]-azepine with S-methylthiourea)
    Aminobenzylamines are commercially obtainable, may be prepared analogously to Monatsh. Chem. (1969), 100(4) or by corresponding methods known to the skilled man.
    Aminobenzimidazoles are commercially obtainable, may be prepared analogously to Olguín, Luís F.; Synlett (2005), (2), 340-342, Bapat; Shirsat, Indian J. Chem.; 3; 1965; 81, Ainsworth, D. P.; Suschitzky, H. J. Chem. Soc., Org. (1966), (1), 111-13 or by corresponding methods known to the skilled man.
    4-aminoanilines are commercially obtainable, may be prepared analogously to WO 2006/021548 or by corresponding methods known to the skilled man.
    1-methyl-4-piperazin-1-yl-1H-pyridin-2-one may be obtained for example by methylation of 4-benzyloxy-1H-pyridin-2-one and subsequent debenzylation (Gwaltney, S. L. et al, Bioorganic & Medicinal Chemistry Letters (2001), 11(7), 871-874) and reaction with Bocpiperazine (in toluene, 120° C., water separator) with subsequent deprotection or by similar methods known to the skilled man.


Method 1
4-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine




1.5 g Histamine (×2HCl) are dissolved in 100 mL phosphate buffer (pH 7) and combined with 1.6 mL acetaldehyde. The pH of the reaction solution is adjusted to 8 by the addition of 1 N NaOH and the reaction solution is stirred for 5 days at 37° C. Then the pH is adjusted to 12 by the further addition of 1 N NaOH, the solvent is eliminated in vacuo, the residue is suspended in ethanol and filtered to remove any undissolved constituents. After elimination of the ethanol in vacuo a crude product remains, which is further used directly for the following reactions.
Yield: 1.62 g
MS: 138 (M+H)+
4-ethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine is prepared analogously to 4-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine using 2.2 mL propionaldehyde.




Yield: 1.8 g
MS: 152 (M+H)+
Method 2
(R)-6-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine




a) (S)-1-bromomethyl-2-(3H-imidazol-4-yl)-ethylamine
900 mg (S)-histidinol (×2HCl) are dissolved in 20 mL HBr in acetic acid (32%) and heated to 110° C. in the microwave for 6 h. The solvent is eliminated in vacuo, the residue is dissolved in ethanol and again freed from the solvent in vacuo. This crude product is used in the next reaction step without further purification.
Yield: 1.5 g
MS: 204/206 (M+H)+
b) (R)-2-(3H-imidazol-4-yl)-1-methyl-ethylamine
1.5 g (S)-1-bromomethyl-2-(3H-imidazol-4-yl)-ethylamine and 1.87 g sodium acetate are dissolved in 94 mL acetic acid (10%). After the addition of 400 mg palladium/C the suspension is shaken under 3.5 bar H2 pressure at RT for about 60 h. After the catalyst has been filtered off the solvent is eliminated in vacuo and the crude product is used without further purification in the following reaction step.
c) (R)-6-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
0.5 g (R)-2-(3H-imidazol-4-yl)-1-methyl-ethylamine are dissolved in 50 mL phosphate buffer (pH 7) and combined with 1.35 mL formaldehyde. The pH is adjusted to 8 by the addition of 1 N NaOH and the reaction solution is stirred for 12 h at 37° C. Then by the further addition of 1 N NaOH the pH is adjusted to 12, the solvent is eliminated in vacuo, the residue is suspended in ethanol and filtered to remove any undissolved constituents. After elimination of the ethanol in vacuo a crude product is left which is further used directly for the following reactions.

    (S)-6-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine is prepared analogously to
    (R)-6-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine using 900 mg (R)-histidinol (×2HCl).






Method 3
7-methyl-3a.4,5,6,7.7a-hexahydro-1H-imidazo[4,5-c]pyridine




a) (1-trityl-1H-imidazol-4-yl)-acetonitrile
2.5 g (1H-imidazol-4-yl)-acetonitrile are dissolved in 20 mL DMF. After the addition of 3.6 mL triethylamine and 7.25 g chlorotriphenylmethane the suspension is left for 60 h at RT with stirring. Water and ethyl acetate are added, the organic phase is separated off, dried with MgSO4 and the solvent is eliminated in vacuo.
Yield: 8.15 g
MS: 243 (CPh3+)
b) 2-(1-trityl-1H-imidazol-4-yl)-propionitrile
9.2 g (1-trityl-1H-imidazol-4-yl)-acetonitrile are dissolved in 120 mL THF, the solution is cooled to −5° C. and 1.8 mL methyl iodide and 1.08 g sodium hydride (60%) are added. The suspension is stirred for 12 h at RT and then applied directly to RP gel and purified by RP chromatography (C18, 10/90 to 90/10 acetonitrile/water in 15 min-0.2% formic acid is added to both solvents).
Yield: 3.23 g
MS: 243 (CPh3+)
c) 2-(1-trityl-1H-imidazol-4-yl)-propylamine
3.2 g 2-(1-trityl-1H-imidazol-4-yl)-propionitrile are dissolved in 150 mL methanolic ammonia (7 mol/L) and Raney nickel is added. After 12 h and 4 bar H2 pressure the catalyst is filtered off and the solvent is eliminated in vacuo. This crude product is used in the following reaction step without further purification.
Yield: 3.2 g
MS: 243 (CPh3+)
d) 7-methyl-3a.4,5,6,7.7a-hexahydro-1H-imidazo[4,5-c]pyridine
3.2 g 2-(1-trityl-1H-imidazol-4-yl)-propylamine is suspended in aqueous HCl (1 N). After the addition of 2.9 mL formaldehyde the mixture is heated to 95° C. with stirring. After 5 h it is cooled to RT, suction filtered to remove the precipitate formed and the solvent is eliminated in vacuo. This crude product is used in the following reaction step without further purification.
Yield: 2.47 g
MS: 138 (M+H)+
Example 1
2-(4-piperazin-1-yl-phenylamino)-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-methoxy-pyrimidine




a) benzyl 4-(4-nitro-phenyl)-piperazine-1-carboxylate
3.76 mL 4-fluoronitrobenzene are dissolved in 40 mL DMA and combined with 9.25 mL N-ethyldiisopropylamine and 7.6 mL 1-(benzyloxycarbonyl)-piperazine. The reaction mixture is stirred for 18 h at 80° C. Then the solvent is eliminated in vacuo and the crude product is purified by chromatography. The carrier material used is silica gel and the eluant is a mixture consisting of cyclohexane/ethyl acetate (50/50).
Yield: 11.28 g
MS (ESI): 342 (M+H)+
b) benzyl 4-(4-amino-phenyl)-piperazine-1-carboxylate
11.28 g benzyl 4-(4-nitro-phenyl)-piperazine-1-carboxylate are dissolved in 500 mL MeOH and combined with 1 g Raney nickel. The mixture is hydrogenated for 18 h at 5 bar H2 pressure. Then the mixture is filtered to remove the catalyst, 70 mL of 1 N aqueous hydrochloric acid are added and the solvent is eliminated in vacuo.
Yield: 10.89 g
MS (ESI): 312 (M+H)+
c) 2-chloro-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-methoxy-pyrimidine
1 g 2,4-dichloro-5-methoxy-pyrimidine are dissolved in 4 mL butanol and combined with 1.04 g 4,5,6,7-tetrahydroimidazopyridine dihydrochloride and 2.96 mL ethyldiisopropylamine. This mixture is stirred for 16 h at 50° C. and then the solvent is eliminated in vacuo. The crude mixture is purified by column chromatography. The carrier material used is C18-RP-silica gel and a gradient is run through which consists at the starting point of 95% water and 5% acetonitrile and at the finishing point of 70% water and 30% acetonitrile. 0.2% formic acid is added to both eluants. The suitable fractions are freeze-dried.
Yield: 0.47 g
MS (ESI): 266 (M+H)+
d) 2-(4-piperazin-1-yl-phenylamino)-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-methoxy-pyrimidine
100 mg 2-chloro-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-methoxy-pyrimidine are suspended in 0.26 mL 1,4-dioxane and 40 μL water and combined with 196 mg benzyl 4-(4-amino-phenyl)-piperazine-1-carboxylate hydrochloride (prepared according to Method 4). This mixture is heated to 95° C. and stirred for 20 h at this temperature. The suspension obtained is diluted with DMF and then purified by column chromatography. The carrier material used is C18-RP-silica gel and a gradient is run through which consists at the starting point of 95% water and 5% acetonitrile and at the finishing point of 70% water and 30% acetonitrile. 0.2% formic acid is added to both eluants. The suitable fractions are freeze-dried. 140 mg of the intermediate product thus obtained are combined with 15 mL DMF, 8 mL water and 30 mg palladium hydroxide and hydrogenated for 2 h at 7 bar H2 pressure. The catalyst is filtered off and the solvent is eliminated in vacuo.
Yield: 0.47 g
UV max: 282 nM
MS (ESI): 407 (M+H)+
Example 2-52
The following compounds are prepared by a process analogous to that described in Example 1. The preparation of 2-chloro-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-dimethylamino-pyrimidine is described in Example 63.
















 












MS (ESI)
UV max


#
R2
(M + H)+
[nm]













2




533
290


 


3




435
290


 


4




497
266/286


 


5




498
246/290


 


6




547
290


 


7




447
285


 


8




519
290


 


9




446
294


 


10




512
290


 


11




462
290


 


12




607
298


 


13




541
290


 


14




477
290


 


15




433
294


 


16




449
294


 


17




449
294


 


18




435
294


 


19




435
294


 


20




449
254


 


21




455
290


 


22




510
290


 


23




469
290


 


24




520
246


 


25




420
290


 


26




455
295


 


27




469
295


 


28




454
290


 


29




438
290


 


30




407
295


 


31




517
290


 


32




402
298


 


33




433
300


 


34




551
290


 


35




535
290


 


36




462
294


 


37




435
290


 


38




502
290


 


39




565
294


 


40




434
290


 


41




455
290


 


42




504
290


 


43




449
290


 


44




448
246, 286


 


45




474
294


 


46




448
290


 


47




429
286


 


48




464
294


 


49




422
322


 


50




436
286


 


51




453
290


 


52




469
294









Example 53
2-[4-(4-isopropyl)-(piperazin-1-yl-phenylamino)-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-methoxy-pyrimidine




30 mg 2-(4-piperazin-1-yl-phenylamino)-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-methoxy-pyrimidine (see Example 1) are dissolved in 0.2 mL DMF. After the addition of 2 μL glacial acetic acid, 11 μL acetone and 78 mg sodium triacetoxyborohydride the suspension is stirred for 3 h at RT. After the addition of 100 μL water the reaction solution is purified by chromatography. The carrier material used is C18-RP-silica gel and a gradient is run through which consists at the starting point of 85% water and 15% acetonitrile and at the finishing point of 5% water and 95% acetonitrile. 0.2% NH3/KHCO3 is added to both eluants. The suitable fractions are freeze-dried.
Yield: 22 mg
UV max: 282 nM
MS (ESI): 449 (M+H)+
Example 54-62
The following compounds are prepared by a process analogous to that described in Example 53. The preparation of 2-chloro-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-dimethylamino-pyrimidine is described in Example 63.
















 













UV




MS (ESI)
max


#
R2
(M + H)+
[nm]





54 

460
290


 


55




532
290


 


56




532
286


 


57




504
290


 


58




562
278


 


59




476
294


 


60




462
290


 


61




474
290


 


62




449
294









Example 63
2-(4-dimethylaminomethyl-phenylamino)-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-dimethylamino-1-pyrimidine




a) 2-chloro-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-dimethylamino-pyrimidine
5 g of 2,4-dichloro-5-dimethylamino-pyrimidine are dissolved in 30 mL isopropanol and combined with 5.82 g 4,5,6,7-tetrahydroimidazopyridine dihydrochloride and 6.06 g potassium carbonate. After 6 and 8 days in each case 1 g of 4,5,6,7-tetrahydroimidazopyridine dihydrochloride and 1 g potassium carbonate are added. In all, the mixture is stirred for 10 days at 25° C. The reaction mixture is diluted with 400 mL water and stirred for 1 h. The precipitate formed is suction filtered, washed and dried.
Yield: 6.24 g
MS (ESI): 279 (M+H)+
b) 2-(4-dimethylaminomethyl-phenylamino)-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-dimethylamino-pyrimidine
50 mg 2-chloro-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-dimethylamino-pyrimidine are suspended in 60 μL of 1,4-dioxane, 20 μL water and 90 μL of a 5 M hydrochloric acid (in 1,4-dioxane) and mixed with 55 mg 4-dimethylaminomethyl-phenylamine. This mixture is heated to 95° C. and stirred for 20 h at this temperature. The suspension obtained is diluted with DMF and then purified by column chromatography. The carrier material used is C18-RP-silica gel and a gradient is run through which consists at the starting point of 95% water (10 mM ammonium hydrogen carbonate and 38 mM ammonia) and 5% acetonitrile and at the finishing point of 50% water and 50% acetonitrile. The fractions are freeze-dried. The residue is taken up in acetonitrile, combined with aqueous hydrochloric acid and freeze-dried once more.
Yield: 8 mg
UV max: 290 nM
MS (ESI): 393 (M+H)+
Example 64-191
The following compounds are prepared by a process analogous to that described in Example 63.
















 
















MS (ESI)
UV max


#
R1
R2
R3
(M + H)+
[nm]















64








—NMe2
527
290


 


65








—NMe2
458
270; 346


 


66








—NMe2
402
302-306


 


68








—NMe2
439
230; 326


 


69








—NMe2
407
242; 290


 


70








—NMe2
439
314


 


71








—NMe2
444
234; 254; 318


 


72








—NMe2
391
230


 


73








—NMe2
393
286


 


74








—NMe2
391
218; 310


 


77








—NMe2
389
274


 


78








—NMe2
429
218-222; 286


 


79








—NMe2
379
250


 


80








—NMe2
419
246; 258


 


81








—NMe2
393
238


 


82








—NMe2
391
238


 


83








—NMe2
433
222-234; 286-290


 


84








—NMe2
435
234-238


 


85








—NMe2
407
306


 


86








—NMe2
393
290


 


87








—NMe2
404
230, 282, 310


 


88








—NMe2
379
294


 


89








—NMe2
407
285


 


90








—NMe2
416
260, 285


 


91








—NMe2
417
285


 


92








—NMe2
435
285


 


93








—NMe2
461
290


 


94








—NMe2
463
285


 


95








—NMe2
501
282


 


96








—NMe2
447
290


 


97








—NMe2
461
290


 


98








—NMe2
393
295


 


99








—NMe2
419
290


 


100








—NMe2
427
305


 


101








—NMe2
517
290


 


103








—NMe2
447
286


 


104








—NMe2
461
258, 282


 


106








—NMe2
390
250, 326


 


107








—NMe2
392
282, 306


 


108








—NMe2
442
266, 342


 


109








—NMe2
447
250, 290


 


110








—NMe2
391
286


 


111








—NMe2
463/465
290


 


112








—NMe2
420
290


 


113








—NMe2
452
290


 


114








—NMe2
448
290


 


115








—NMe2
448
282


 


116








—NMe2
354
278


 


117








—NMe2
391
290


 


118








—NMe2
455
290


 


119








—NMe2
435
290


 


121








—NMe2
390
242, 278, 314


 


122








—NMe2
404
238, 282


 


123








—NMe2
406
286


 


124








—NMe2
420
238, 278, 314


 


125








—NMe2
434
238, 282, 314


 


126








—NMe2
448
238, 278, 314


 


128








—NMe2
481
226, 266, 318


 


129








—NMe2
436
286


 


130








—NMe2
397
274, 318


 


131








—NMe2
455
222, 262, 314


 


132








—NMe2
418
238, 282


 


133








—NMe2
404
346


 


134








—NMe2
416
282


 


135








—NMe2
461
294


 


136








—NMe2
434
290


 


137








—NMe2
421
290


 


138








—NMe2
448
290


 


139








—NMe2
448
290


 


140








—NMe2
434
290


 


141








—NMe2
448
286


 


142








—NMe2
462
286


 


143








—NMe2
462
286


 


144








—NMe2
391
282


 


145








—NMe2
468
330


 


146








—NMe2
366
282


 


147








—NMe2
404
298, 262


 


148








—NMe2
414
310


 


149








—NMe2
392
230, 290


 


150








—NMe2
392
326


 


151








—NMe2
393
286


 


152








—NMe2
429
290


 


153








—NMe2
433
290


 


154








—NMe2
442
322


 


155








—NMe2
414
290


 


156








—NMe2
366
294


 


157








—NMe2
404
286


 


158








—NMe2
378
242, 282


 


159








—NMe2
378
338


 


160








—NMe2
448
274


 


161








—NMe2
462
278


 


162








—NMe2
452
290


 


163








—NMe2
468
290


 


164








—NMe2
448
290


 


165








—NEtMe
448
290


 


166








—OMe
391
242, 274, 306


 


167








—OMe
434
278


 


168








—OMe
435
282


 


169








—OMe
421
282


 


170








—OMe
435
282


 


171








—OMe
449
282


 


172








—OMe
467
278


 


173








—OMe
449
282


 


174








—OMe
481
278


 


175








—OMe
422
282


 


176








—OMe
449
274


 


177








—OMe
435
274


 


178








—OMe
435
282


 


179








—OMe
435
282


 


180








—OMe
435
282


 


181












431
282


 


182












445
282


 


183












433
282


 


184












448
290


 


185












510
290


 


186












420
290


 


187












433
334, 246


 


188












420
334, 246


 


189












447
334, 246


 


190












418
278


 


191












432
326









Example 192
2-[4-(2-pyrrolidin-1-yl-ethylcarbamoyl)-phenylamino]-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-dimethylamino-1-pyrimidine




35 mg 2-(4-carboxy-phenylamino)-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-dimethylamino-pyrimidine (prepared analogously to Example 63) is dissolved in 0.2 mL DMF, and combined with 64 μL triethylamine, 33 mg O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium-tetrafluoroborate and 1-(2-aminoethyl)-pyrrolidine. After being stirred for 15 h at RT the reaction solution is purified by column chromatography. The carrier material used is C18-RP-silica gel and a gradient is run through which consists at the starting point of 80% water (10 mM ammonium hydrogen carbonate and 38 mM ammonia) and 20% acetonitrile and at the finishing point of 35% water and 65% acetonitrile. Fractions are freeze-dried. The residue is taken up in acetonitrile, combined with aqueous hydrochloric acid and freeze-dried again.
Yield: 40 mg
UV max: 315 nM
MS (ESI): 476 (M+H)+
Example 193-232
The following compounds are prepared by a process analogous to that described in Example 192. The acid component for Examples 228 to 232 may be obtained by saponification of the methyl ester (see Example 14).
















 












MS (ESI)
UV max


#
R2
(M + H)+
[nm]





193




421
314


 


194




462
306


 


195




478
306


 


196




433
314


 


197




425
314


 


198




435
314


 


199




437
314


 


200




407
302


 


201




449
306


 


202




498
322


 


203




495
334-342


 


204




509
322


 


205




553
322-326


 


206




455
302


 


207




469
222-226


 


208




546
294


 


209




518
294-298


 


210




525
262; 302-306


 


211




524
242-246; 302-306


 


212




538
302-306


 


213




592
262-270; 298-306


 


214




506
302-310


 


215




490
302-310


 


216




490
306-310


 


217




526
250-254; 306-310


 


218




560
302-306


 


219




553
302-310


 


220




525
246-250; 302-310


 


221




474
306-310


 


222




547
302-310


 


223




539
302-310


 


224




575
302-310


 


225




483
306


 


226




476
314


 


227




490
302


 


228




476
315


 


229




566
290


 


230




566
286


 


231




532
290


 


232




560
290









Example 233
2-(3-(4-cyanomethyl-piperazin-1-yl)-phenylamino)-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-dimethylamino-1-pyrimidine




45 mg 2-(3-piperazin-1-yl-phenylamino)-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-methoxy-pyrimidine (prepared analogously to Example 1) is dissolved in 0.5 mL DMA and combined with 6.8 μL chloroacetonitrile and 15.2 mg potassium carbonate 33 mg. After being stirred for 15 h at RT the reaction solution is purified by column chromatography. The carrier material used is C18-RP-silica gel and a gradient is run through which consists at the starting point of 80% water (10 mM ammonium hydrogen carbonate and 20 mM ammonia) and 20% acetonitrile and at the finishing point of 35% water and 65% acetonitrile. The appropriate fractions are freeze-dried. The residue is taken up in acetonitrile, combined with aqueous hydrochloric acid and freeze-dried once again.
Yield: 17.5 mg
UV max: 244 nM
MS (ESI): 459 (M+H)+
Examples 234-236
The following compounds are prepared by a process analogous to that described in Example 233. The corresponding amines are described in the literature or are commercially obtainable.
















 












MS (ESI)
UV max


#
R2 
(M + H)+
[nm]





234




501
294


 


235




487
286


 


236




502
290









Example 237
2-[4-(furan-3-yl)-phenylamino]-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-dimethylamino-1-pyrimidine




a) 4-furan-3-yl-1-nitrobenzene
200 mg 4-bromonitrobenzene, 110.8 mg furan-3-boric acid and 162 mg palladium/C are dissolved in 3 mL 1,4-dioxane. Then 965.3 mg caesium carbonate (dissolved in 586 μL water) are added. The reaction is completed in the microwave (110° C.) after 100 min. After aqueous working up the mixture is extracted with ethyl acetate and died on magnesium sulphate. The solvent is eliminated in vacuo. This crude product is used in the following reaction without further purification.
b) 4-furan-3-yl-phenylamine
277 mg 4-furan-3-yl-1-nitrobenzene are dissolved in 40 ml of methanol and combined with 200 mg palladium/C. The suspension is shaken at 25° C. for 60 h under a H2 pressure of 5 bar. Then the solvent is eliminated in vacuo. The crude mixture is purified by column chromatography. The carrier material used is silica gel and the mobile phase used is a solvent mixture of cyclohexane/ethyl acetate 50/50. The suitable fractions are freed from the solvent in vacuo.
Yield: 82 mg
MS (ESI): 160 (M+H)+
c) 2-[4-(furan-3-yl)-phenylamino]-4-(3,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-5-dimethylamino-pyrimidine
This compound is prepared analogously to Example 63 using 4-furan-3-yl-phenylamine instead of 4-dimethylaminomethyl-phenylamine.
Yield: 40 mg
UV max: 302 nM
MS (ESI): 402 (M+H)+
Example 238-243
The following compounds are prepared by a process analogous to that described in Example 237. The corresponding amines are described in the literature or are commercially obtainable.
















 












MS (ESI)
UV max


#
R2
(M + H)+
[nm]





238




413
330


 


239




413
317


 


240




414
325


 


241




413
326


 


242




401
305


 


243




401
318









The following Examples describe the biological activity of the compounds according to the invention without restricting the invention to these Examples.
The effect of the compounds according to the invention on various kinases, for example on serine-threonine kinase PDK1, is determined in in vitro kinase assays with recombinantly prepared protein. The compounds in this assay exhibit good to very good activity, i.e. for example an IC50 value of less than 1 μmol/L, generally less than 0.1 μmol/L.
Example PDK1 Kinase Assay
Recombinant human PDK1 enzyme (aa 52-556) attached to His6 at its N-terminal end is isolated from Baculovirus-infected insect cells. Purified enzyme may also be obtained for example through Upstate.
The following components are combined in a well of a 96-well round-bottomed plate (Greiner bio-one, No. 650101):

    
    
        7.5 μL of the compound to be tested in a variable concentration (e.g. beginning at 10 μM, and dilution in 1:5) in 3.33% DMSO (1% DMSO final concentration)/assay buffer (50 mM Tris pH 7.5, 0.05% β-mercaptoethanol, 10 mM magnesium acetate)
        7.5 μL PDK1 (10 ng/well) and PDKtide (KTFCGTPEYLAPEVRREPRILSEEEQEMFRDFDYIADWC) synthesised by Pepceuticals Limited, Nottingham, United Kingdom; 25 μM final concentration; PDK1 and PDKtide are correspondingly diluted together in assay buffer; PDKtide is present in this mixture as an 83.3 μM solution)
        10 μL ATP solution (25 μM ATP with 0.5 μCi/well of gamma-P33-ATP)
    
    


The reaction is started by adding the ATP solution and incubated for 30 min at RT; at the start of the reaction the plates are shaken gently. The reaction is stopped by the addition of 5 μL/well 0.5 M phosphoric acid (H3PO4) and incubated for about 20 min at RT. The precipitate is transferred by harvesting onto filter plates (96-well microtitre filter plate: UniFilter GF/C; Perkin Elmer; No. 6005174), then washed 6 times with 50 mM H3PO4 and dried at 60° C. Then the plate is stuck down with sealing tape, 25 μL/well of scintillation solution (Microscint 0; Perkin Elmer; No. 6013611) are added and the amount of P33 precipitated is measured using the Wallac Betacounter. The measurement data are evaluated using the Standard Graphpad software.
The antiproliferative activity of the compounds according to the invention is determined on cultivated human tumour cells, for example on PC-3 cells. The compounds exhibit good to very good activity, i.e. for example an EC50 value of less than 5 μmol L, generally less than 1 μmol L in the PC-3 proliferation test.
Measurement of the Inhibition of Proliferation on Cultivated Human Tumour Cells
To measure proliferation on cultivated human tumour cells, cells of prostate carcinoma tumour cell line PC-3 (obtained from American Type Culture Collection (ATCC)) are cultivated in Ham's F12 Medium (Gibco) and 10% foetal calf serum (Gibco) and harvested in the log growth phase. Then the PC-3 cells are placed in 96-well plates (Costar) at a density of 1000 cells per well and incubated overnight in an incubator (at 37° C. and 5% CO2), while on each plate 16 wells are used as controls (8 wells with cells to which only DMSO solution has been added (should yield 30-50% maximum value of reduced AlamarBlue), 4 wells containing only medium (medium control, after the addition of oxidised AlamarBlue reagent the background signal is obtained) and 4 wells where again only medium is added (after the addition of reduced AlamarBlue reagent it acts as a maximum value)). The active substances are added to the cells in various concentrations (dissolved in DMSO; DMSO final concentration: 0.1% or 1%) (in each case as a double or triple measurement). After 5 days' incubation 20 μl AlamarBlue reagent (Serotec) are added to each well, and the cells are incubated for a further 5-7 hours. As a control, 20 μl reduced AlamarBlue reagent is added to each of 4 wells. After incubation the colour change of the AlamarBlue reagent in the individual wells is determined in a SpectraMax Photometer (Molecular Devices) (extinction 530 nm, emission 590 nm, 5 sec measuring time). The amount of AlamarBlue reagent reacted represents the metabolic activity of the cells. The relative cell activity is calculated in relation to the control (PC-3 cells without inhibitor) and the active substance concentration which inhibits the cell activity by 50% (EC50) is derived. The values are calculated from the average of two or three individual measurements.
The compounds according to the invention are also tested accordingly on other tumour cells. For example these compounds are effective on carcinomas of all kinds of tissue (e.g. gliomas (U87), sarcoma (e.g. MES-SA, SK-UT-1B), breast (MDA-MB468), colon (HCT 116), lung (H460)) and could be used in indications of this kind, particularly in indications which have activating changes in the PI3K-AKT-PDK1 signal pathway. This demonstrates the wide range of applications for the compounds according to the invention for the treatment of all kinds of tumour types.
On the basis of their biological properties the new compounds of general formula (1) or (1A), the isomers and the physiologically acceptable salts thereof are therefore suitable for treating diseases characterised by excessive or abnormal cell proliferation.
Such diseases include for example: viral infections (e.g. HIV and Kaposi's sarcoma); inflammatory and autoimmune diseases (e.g. colitis, arthritis, Alzheimer's disease, glomerulonephritis and wound healing); bacterial, fungal and/or parasitic infections; leukaemias, lymphomas and solid tumours (e.g. carcinomas and sarcomas), skin diseases (e.g. psoriasis); diseases based on hyperplasia which are characterised by an increase in the number of cells (e.g. fibroblasts, hepatocytes, bones and bone marrow cells, cartilage or smooth muscle cells or epithelial cells (e.g. endometrial hyperplasia)); bone diseases and cardiovascular diseases (e.g. restenosis and hypertrophy).
For example, the following cancers may be treated with compounds according to the invention, without being restricted thereto: brain tumours such as for example acoustic neurinoma, astrocytomas such as pilocytic astrocytomas, fibrillary astrocytoma, protoplasmic astrocytoma, gemistocytary astrocytoma, anaplastic astrocytoma and glioblastoma, brain lymphomas, brain metastases, hypophyseal tumour such as prolactinoma, HGH (human growth hormone) producing tumour and ACTH producing tumour (adrenocorticotropic hormone), craniopharyngiomas, medulloblastomas, meningeomas and oligodendrogliomas; nerve tumours (neoplasms) such as for example tumours of the vegetative nervous system such as neuroblastoma sympathicum, ganglioneuroma, paraganglioma (pheochromocytoma, chromaffinoma) and glomus-caroticum tumour, tumours on the peripheral nervous system such as amputation neuroma, neurofibroma, neurinoma (neurilemmoma, Schwannoma) and malignant Schwannoma, as well as tumours of the central nervous system such as brain and bone marrow tumours; intestinal cancer such as for example carcinoma of the rectum, colon, anus, small intestine and duodenum; eyelid tumours such as basalioma or basal cell carcinoma; pancreatic cancer or carcinoma of the pancreas; bladder cancer or carcinoma of the bladder; lung cancer (bronchial carcinoma) such as for example small-cell bronchial carcinomas (oat cell carcinomas) and non-small cell bronchial carcinomas such as plate epithelial carcinomas, adenocarcinomas and large-cell bronchial carcinomas; breast cancer such as for example mammary carcinoma such as infiltrating ductal carcinoma, colloid carcinoma, lobular invasive carcinoma, tubular carcinoma, adenocystic carcinoma and papillary carcinoma; non-Hodgkin's lymphomas (NHL) such as for example Burkitt's lymphoma, low-malignancy non-Hodgkin's lymphomas (NHL) and mucosis fungoides; uterine cancer or endometrial carcinoma or corpus carcinoma; CUP syndrome (Cancer of Unknown Primary); ovarian cancer or ovarian carcinoma such as mucinous, endometrial or serous cancer; gall bladder cancer; bile duct cancer such as for example Klatskin tumour; testicular cancer such as for example seminomas and non-seminomas; lymphoma (lymphosarcoma) such as for example malignant lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas (NHL) such as chronic lymphatic leukaemia, leukaemic reticuloendotheliosis, immunocytoma, plasmocytoma (multiple myeloma), immunoblastoma, Burkitt's lymphoma, T-zone mycosis fungoides, large-cell anaplastic lymphoblastoma and lymphoblastoma; laryngeal cancer such as for example tumours of the vocal cords, supra-glottal, glottal and subglottal laryngeal tumours; bone cancer such as for example osteochondroma, chondroma, chondroblastoma, chondromyxoid fibroma, osteoma, osteoid osteoma, osteoblastoma, eosinophilic granuloma, giant cell tumour, chondrosarcoma, osteosarcoma, Ewing's sarcoma, reticulo-sarcoma, plasmocytoma, giant cell tumour, fibrous dysplasia, juvenile bone cysts and aneurysmatic bone cysts; head and neck tumours such as for example tumours of the lips, tongue, floor of the mouth, oral cavity, gums, palate, salivary glands, throat, nasal cavity, paranasal sinuses, larynx and middle ear; liver cancer such as for example liver cell carcinoma or hepatocellular carcinoma (HCC); leukaemias, such as for example acute leukaemias such as acute lymphatic/lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML); chronic leukaemias such as chronic lymphatic leukaemia (CLL), chronic myeloid leukaemia (CML); stomach cancer or gastric carcinoma such as for example papillary, tubular and mucinous adenocarcinoma, signet ring cell carcinoma, adenosquamous carcinoma, small-cell carcinoma and undifferentiated carcinoma; melanomas such as for example superficially spreading, nodular, lentigo-maligna and acral-lentiginous melanoma; renal cancer such as for example kidney cell carcinoma or hypernephroma or Grawitz's tumour; oesophageal cancer or carcinoma of the oesophagus; penile cancer; prostate cancer; throat cancer or carcinomas of the pharynx such as for example nasopharynx carcinomas, oropharynx carcinomas and hypopharynx carcinomas; retinoblastoma; vaginal cancer or vaginal carcinoma; plate epithelial carcinomas, adenocarcinomas, in situ carcinomas, malignant melanomas and sarcomas; thyroid carcinomas such as for example papillary, follicular and medullary thyroid carcinoma, as well as anaplastic carcinomas; spinalioma, epidormoid carcinoma and plate epithelial carcinoma of the skin; thymomas, cancer of the urethra and cancer of the vulva.
The new compounds may be used for the prevention, short-term or long-term treatment of the above-mentioned diseases, optionally also in combination with radiotherapy or other “state-of-the-art” compounds, such as e.g. cytostatic or cytotoxic substances, cell proliferation inhibitors, anti-angiogenic substances, steroids or antibodies.
The compounds of general formula (1) or (1A) may be used on their own or in combination with other active substances according to the invention, optionally also in combination with other pharmacologically active substances.
Chemotherapeutic agents which may be administered in combination with the compounds according to the invention include, without being restricted thereto, hormones, hormone analogues and antihormones (e.g. tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, flutamide, nilutamide, bicalutamide, aminoglutethimide, cyproterone acetate, finasteride, buserelin acetate, fludrocortisone, fluoxymesterone, medroxyprogesterone, octreotide), aromatase inhibitors (e.g. anastrozole, letrozole, liarozole, vorozole, exemestane, atamestane), LHRH agonists and antagonists (e.g. goserelin acetate, luprolide), inhibitors of growth factors (growth factors such as for example “platelet derived growth factor” and “hepatocyte growth factor”, inhibitors are for example “growth factor” antibodies, “growth factor receptor” antibodies and tyrosinekinase inhibitors, such as for example cetuximab, gefitinib, imatinib, lapatinib and trastuzumab); antimetabolites (e.g. antifolates such as methotrexate, raltitrexed, pyrimidine analogues such as 5-fluorouracil, capecitabin and gemcitabin, purine and adenosine analogues such as mercaptopurine, thioguanine, cladribine and pentostatin, cytarabine, fludarabine); antitumour antibiotics (e.g. anthracyclins such as doxorubicin, daunorubicin, epirubicin and idarubicin, mitomycin-C, bleomycin, dactinomycin, plicamycin, streptozocin); platinum derivatives (e.g. cisplatin, oxaliplatin, carboplatin); alkylation agents (e.g. estramustin, meclorethamine, melphalan, chlorambucil, busulphan, dacarbazin, cyclophosphamide, ifosfamide, temozolomide, nitrosoureas such as for example carmustin and lomustin, thiotepa); antimitotic agents (e.g. Vinca alkaloids such as for example vinblastine, vindesin, vinorelbin and vincristine; and taxanes such as paclitaxel, docetaxel); topoisomerase inhibitors (e.g. epipodophyllotoxins such as for example etoposide and etopophos, teniposide, amsacrin, topotecan, irinotecan, mitoxantron) and various chemotherapeutic agents such as amifostin, anagrelid, clodronat, filgrastin, interferon alpha, leucovorin, rituximab, procarbazine, levamisole, mesna, mitotane, pamidronate and porfimer.
Suitable preparations include for example tablets, capsules, suppositories, solutions,—particularly solutions for injection (s.c., i.v., i.m.) and infusion—elixirs, emulsions or dispersible powders. The content of the pharmaceutically active compound(s) should be in the range from 0.1 to 90 wt.-%, preferably 0.5 to 50 wt.-% of the composition as a whole, i.e. in amounts which are sufficient to achieve the dosage range specified below. The doses specified may, if necessary, be given several times a day.
Suitable tablets may be obtained, for example, by mixing the active substance(s) with known excipients, for example inert diluents such as calcium carbonate, calcium phosphate or lactose, disintegrants such as corn starch or alginic acid, binders such as starch or gelatine, lubricants such as magnesium stearate or talc and/or agents for delaying release, such as carboxymethyl cellulose, cellulose acetate phthalate, or polyvinyl acetate. The tablets may also comprise several layers.
Coated tablets may be prepared accordingly by coating cores produced analogously to the tablets with substances normally used for tablet coatings, for example collidone or shellac, gum arabic, talc, titanium dioxide or sugar. To achieve delayed release or prevent incompatibilities the core may also consist of a number of layers. Similarly the tablet coating may consist of a number of layers to achieve delayed release, possibly using the excipients mentioned above for the tablets.
Syrups or elixirs containing the active substances or combinations thereof according to the invention may additionally contain a sweetener such as saccharine, cyclamate, glycerol or sugar and a flavour enhancer, e.g. a flavouring such as vanillin or orange extract. They may also contain suspension adjuvants or thickeners such as sodium carboxymethyl cellulose, wetting agents such as, for example, condensation products of fatty alcohols with ethylene oxide, or preservatives such as p-hydroxybenzoates.
Solutions for injection and infusion are prepared in the usual way, e.g. with the addition of isotonic agents, preservatives such as p-hydroxybenzoates, or stabilisers such as alkali metal salts of ethylenediamine tetraacetic acid, optionally using emulsifiers and/or dispersants, whilst if water is used as the diluent, for example, organic solvents may optionally be used as solvating agents or dissolving aids, and transferred into injection vials or ampoules or infusion bottles.
Capsules containing one or more active substances or combinations of active substances may for example be prepared by mixing the active substances with inert carriers such as lactose or sorbitol and packing them into gelatine capsules.
Suitable suppositories may be made for example by mixing with carriers provided for this purpose, such as neutral fats or polyethyleneglycol or the derivatives thereof.
Excipients which may be used include, for example, water, pharmaceutically acceptable organic solvents such as paraffins (e.g. petroleum fractions), vegetable oils (e.g. groundnut or sesame oil), mono- or polyfunctional alcohols (e.g. ethanol or glycerol), carriers such as e.g. natural mineral powders (e.g. kaolins, clays, talc, chalk), synthetic mineral powders (e.g. highly dispersed silicic acid and silicates), sugars (e.g. cane sugar, lactose and glucose) emulsifiers (e.g. lignin, spent sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulphate).
The preparations are administered by the usual methods, preferably by oral or transdermal route, most preferably by oral route. For oral administration the tablets may, of course contain, apart from the abovementioned carriers, additives such as sodium citrate, calcium carbonate and dicalcium phosphate together with various additives such as starch, preferably potato starch, gelatine and the like. Moreover, lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used at the same time for the tabletting process. In the case of aqueous suspensions the active substances may be combined with various flavour enhancers or colourings in addition to the excipients mentioned above.
For parenteral use, solutions of the active substances with suitable liquid carriers may be used.
The dosage for intravenous use is from 1-1000 mg per hour, preferably between 5 and 500 mg per hour.
However, it may sometimes be necessary to depart from the amounts specified, depending on the body weight, the route of administration, the individual response to the drug, the nature of its formulation and the time or interval over which the drug is administered. Thus, in some cases it may be sufficient to use less than the minimum dose given above, whereas in other cases the upper limit may have to be exceeded. When administering large amounts it may be advisable to divide them up into a number of smaller doses spread over the day.
The formulation examples that follow illustrate the present invention without restricting its scope:
Examples of Pharmaceutical Formulations














A) Tablets
per tablet




















active substance according to formula (1)
100
mg



lactose
140
mg



corn starch
240
mg



polyvinylpyrrolidone
15
mg



magnesium stearate
5
mg




500
mg










The finely ground active substance, lactose and some of the corn starch are mixed together. The mixture is screened, then moistened with a solution of polyvinylpyrrolidone in water, kneaded, wet-granulated and dried. The granules, the remaining corn starch and the magnesium stearate are screened and mixed together. The mixture is compressed to produce tablets of suitable shape and size.














B) Tablets
per tablet




















active substance according to formula (1)
80
mg



lactose
55
mg



corn starch
190
mg



microcrystalline cellulose
35
mg



polyvinylpyrrolidone
15
mg



sodium-carboxymethyl starch
23
mg



magnesium stearate
2
mg




400
mg










The finely ground active substance, some of the corn starch, lactose, microcrystalline cellulose and polyvinylpyrrolidone are mixed together, the mixture is screened and worked with the remaining corn starch and water to form a granulate which is dried and screened. The sodiumcarboxymethyl starch and the magnesium stearate are added and mixed in and the mixture is compressed to form tablets of a suitable size.










C) Ampoule solution



















active substance according to formula (1)
50
mg



sodium chloride
50
mg



water for inj.
5
ml










The active substance is dissolved in water at its own pH or optionally at pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. The solution obtained is filtered free from pyrogens and the filtrate is transferred under aseptic conditions into ampoules which are then sterilised and sealed by fusion. The ampoules contain 5 mg, 25 mg and 50 mg of active substance.

## Claims

1. A compound of the formula (1A),



wherein
Q denotes 5, 6 or 7 membered heterocycloalkyl;
R2 denotes 9 membered heteroaryl, substituted by one or more identical or different R4, or
R2 denotes 9 membered heterocycloalkyl substituted by one or more identical or different R4, or
R2 denotes phenyl substituted by a 5-6 membered heterocycloalkyl, which may optionally be substituted by one or more identical or different Rc and/or Rb, or
R2 denotes phenyl substituted by —NRcRc, —C(O)Rc or —C(O)NRcRc, and
R3 denotes dimethylamino or methoxy, and
R4 denotes a group selected from among Ra, Rb and Ra substituted by one or more identical or different Rc and/or Rb;
each Ra is selected independently of one another from among C1-6alkyl, C3-10cycloalkyl, C4-16cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl;
each Rb is a suitable group and each is independently selected from among ═O, —ORc, C1-3haloalkyloxy, —OCF3, ═S, —SRc, ═NRc, NORc, —NRcRc, halogen, —CF3, —CN, —NC, —OCN, —SCN, —NO2, —S(O)Rc, —S(O)2Rc, —S(O)2ORc, —S(O)NRcRc, —S(O)2NRcRc, —OS(O)Rc, —OS(O)2Rc, —OS(O)2ORc, —OS(O)2NRcRc, —C(O)Rc, —C(O)ORc, —C(O)NRcRc, —CN(Rf)NRcRc, —CN(OH)Rc, —CN(OH)NRcRc, —OC(O)Rc, —OC(O)ORc, —OC(O)NRcRc, —OCN(Rf)NRcRc, —N(Rf)C(O)Rc, —N(Rf)C(S)Rc, —N(Rf)S(O)2Rc, —N(Rf)C(O)ORc, —N(Rf)C(O)NRcRc, —[N(Rf)C(O)]2Rc, —N[C(O)]2Rc, —N[C(O)]2ORc, —[N(Rf)C(O)]2ORc and —N(Rf)CN(Rf)NRcRc;
each Rc independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rd and/or Re selected from among C1-6alkyl, C3-10cycloalkyl, C4-11cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl;
each Rd independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Re and/or Rf selected from among C1-6alkyl, C3-8cycloalkyl, C4-11cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl;
each Re is a suitable group and each is independently selected from among ═O, —ORf, C1-3haloalkyloxy, —OCF3, ═S, —SRf, ═NRf, ═NORf, —NRfRf, halogen, —CF3, —CN, —NC, —OCN, —SCN, —NO2, —S(O)Rf, —S(O)2Rf, —S(O)2ORf, —S(O)NRfRf, —S(O)2NRfRf, —OS(O)Rf, —OS(O)2Rf, —OS(O)2ORf, —OS(O)2NRfRf, —C(O)Rf, —C(O)ORf, —C(O)NRfRf, —CN(Rg)NRfRf, —CN(OH)Rf, —C(NOH)NRfRf, —OC(O)Rf, —OC(O)ORf, —OC(O)NRfRf, —OCN(Rg)NRfRf, —N(Rg)C(O)Rf, —N(Rg)C(S)Rf, —N(Rg)S(O)2Rf, —N(Rd)C(O)ORf, —N(Rg)C(O)NRfRf, and —N(Rg)CN(Rf)NRfRf;
each Rf independently of one another denotes hydrogen or a group optionally substituted by one or more identical or different Rg selected from among C1-6alkyl, C3-8cycloalkyl, C4-11cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkylalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl;
each Rg independently of one another denotes hydrogen, C1-6alkyl, C3-8cycloalkyl, C4-11cycloalkylalkyl, C6-10aryl, C7-16arylalkyl, 2-6 membered heteroalkyl, 3-8 membered heterocycloalkyl, 4-14 membered heterocycloalkyl, 5-12 membered heteroaryl and 6-18 membered heteroarylalkyl,
or a tautomer, racemate, enantiomer, diastereomer or mixture thereof or pharmacologically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of the formula (1A) according to claim 1, or a pharmaceutically effective salts thereof, and an exipient or carrier.

3. A method for the treatment of breast cancer which comprises administering to a host suffering from breast cancer a therapeutically effective amount of a compound according to claim 1.